Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Harrington, Discovery

Harrington Discovery Institute Ohio

14.10.2020 - 18:04:54

Harrington Discovery Institute Announces Award Recipients in New UK Rare Disease Program

their transatlantic partnership to establish the Oxford-Harrington Rare Disease Centre (OHC). The OHC is focused primarily on rare diseases that have a clear genetic basis, present early in life, and fit one of three research themes: neurological disorders, developmental disorders, and cancer. Harrington UK Rare Disease Scholars may have opportunity to utilize Oxford's core labs as well as the OHC Therapeutic Accelerator (planned opening in 2021) for their projects.

"The Harrington model is a bold approach that de-risks clinical drug candidates and validates their commercial potential, making them attractive to for-profit funders who are able to bring them to market. This program is an extraordinary opportunity for UK researchers to help them translate scientific discoveries into medicines that improve the lives and health outcomes of those living with a rare disease," said Peter Worrall, former Chief Financial Officer at Rex Bionics plc, and member, Board of Trustees, Fund for Cures UK.   

Harrington Discovery Institute will raise capital to support the growth of the UK rare disease initiative through Morgan Stanley GIFT Cures, its philanthropic partnership with global financial services firm Morgan Stanley. 

The 2021 Harrington UK Rare Disease Scholar Award recipients, their organizations and fields of research are:

Pietro Fratta, MD, PhD – University College London
Gene Therapy for Kennedy's Disease, a rare neuromuscular disease

Angela Russell, DPhil – University of Oxford 
New Drugs for the Treatment of Duchenne Muscular Dystrophy

Helen Waller-Evans, DPhil – Cardiff University 
Novel Inhibitors to Treat Multiple Lysomal Storage Disorders, causes of widespread organ damage

Wyatt Yue, PhD – University of Oxford 
Inhibitors of Primary Hyperoxaluria, a cause of kidney failure

Haiyan Zhou, MD, PhD – University College London
Novel Therapy for SPTLC1-Related Hereditary Sensory Neuropathy, a cause of shooting pain

@ prnewswire.co.uk